|
Study ID
|
EA 4/033/06
|
|
Investigator
|
Martin Schostak, PD Dr., University Medical Centre Charité, Berlin, Germany
André Schrattenholz, Prof. Dr., ProteoSys AG, Mainz, Germany
|
|
Title
|
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
|
|
Conditions
|
Prostate Cancer
Benign Prostatic Hyperplasia
Prostatic Intraepithelial Neoplasia
|
|
Interventions
|
|
|
Phase
|
N/A
|
|
Purpose
|
Emerging from a differential proteomic study of sample pairs of prostate cancer and benign
tissue, annexin A3 (ANXA3) was chosen as a potential novel biomarker for the early and
non-invasive diagnosis of prostate cancer. We wanted to show or investigate, that:
- ANXA3 can be detected in urine after standard digital rectal examination.
- ANXA3 has better specificities than tPSA, in particular in the grey zone of PSA
- ANXA3 can help avoid unnecessary biopsies
- ANXA3 can in the long run replace PSA as a marker
|
|
Eligibility
|
Ages Eligible: N/A
Genders Eligible:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:- Patients with a histological confirmation of adenocarcinoma of the prostate
- Patients with benign prostatic hyperplasia (confirmed by histology of lance biopsies
or TUR-P)
Exclusion Criteria:- Patients with rectal extirpation
- Patients with renal or bladder tumors
|
|
Study Location
|
N/A
|
|
Contact
|
N/A
|
Information obtained from ClinicalTrials.gov, on
6/19/2013. For additional information about
this and other clinical trials,
visit http://clinicaltrials.gov.
Please refer to this study by its ClinicalTrials.gov identifier:
NCT00400894
|
|